The estimated Net Worth of Ian Fier is at least $4.3 Million dollars as of 7 August 2020. Ian Fier owns over 713 units of Momenta Pharmaceuticals stock worth over $37,418 and over the last 6 years Ian sold MNTA stock worth over $4,265,920.
Ian has made over 35 trades of the Momenta Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently Ian sold 1,808 units of MNTA stock worth $94,323 on 20 August 2020.
The largest trade Ian's ever made was exercising 87,703 units of Momenta Pharmaceuticals stock on 14 January 2020 worth over $1,369,921. On average, Ian trades about 7,926 units every 15 days since 2018. As of 7 August 2020 Ian still owns at least 713 units of Momenta Pharmaceuticals stock.
You can see the complete history of Ian Fier stock trades at the bottom of the page.
Ian's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler, and Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Momenta Pharmaceuticals executives and other stock owners filed with the SEC include: